0

Multiple Sclerosis Therapies Market Expected to Reach $28.00 Billion by 2026—Allied Market Research

 
2022
Multiple Sclerosis Therapies Market

Report Code : A01119

quote Significant rise in number of pipeline drugs is a key factor that contributes toward the growth of the global multiple sclerosis therapies market along with increase in patient base suffering from multiple sclerosis. Furthermore, surge in number of patient assistance programs and similar initiatives undertaken by the government of various countries are anticipated to further boost the demand for multiple sclerosis therapies in coming future. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “Multiple Sclerosis Therapies Market by Type and Route of Administration:  Opportunity Analysis and Industry Forecast, 2019-2026” the global MS therapies market was valued at $22.99 billion in 2018, and is projected to reach $28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026. Multiple sclerosis is categorized as an autoimmune, chronic, and inflammatory disease of the CNS. According to the data published by the National Multiple Sclerosis Society, around 1.0 million individuals have multiple sclerosis in the U.S. alone, and approximately 2.3 million people globally. This number is further expected to continue to grow each year, which, in turn, makes it important to discover multiple sclerosis therapies with improved effectiveness and minimum side effects. Government as well as non-government bodies in developed and emerging regions are contributing funds for R&D of new multiple sclerosis therapies and increasing awareness related to multiple sclerosis.

The global MS therapies market is segmented into type, route of administration, and region. By type, the market is bifurcated into immunosuppressants and immunomodulators. Depending on route of administration, it is divided into oral, injectable, and intravenous. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

On the basis of type, the immunosuppressants segment is expected to grow at a lucrative CAGR of 2.80%, owing to increase in use of immunosuppressive therapies for treating multiple sclerosis in developed countries. Furthermore, the immunosuppressants segment was the highest contributor to the market, owing to their beneficial effects for patients suffering from relapsing-remitting multiple sclerosis (RRMS) by weakening the immune system, thereby suppressing the autoimmune attack in the patient’s body and preventing relapses. In addition, the increase in product approvals for the treatment of MS therapies is anticipated to propel the market growth globally. Currently, the immunosuppressants that have been approved for use only in relapsing forms of MS, include alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta preparations, natalizumab, ocrelizumab, and teriflunomide.

As per route of administration, the oral segment is anticipated to grow significantly in the near future, due to increase in product approval and lesser side effects of medications. The oral route of administration promotes patient satisfaction and increases therapeutic compliance. Significant therapeutic advances in the new orally administered drugs approved for the MS treatment represent boost the growth of the market. Three oral drugs have been approved by regulatory agencies for the treatment of MS, which include fingolimod, teriflunomide, and dimethyl fumarate. The mechanisms of action, efficacy, and safety of these drugs that have yielded positive results in phase III trials, which is a key factor that contributes toward the growth of the global market.

The report provides a comprehensive analysis of the key players operating in the global multiple sclerosis therapies market, which include ABBVIE INC., Bayer AG, Biogen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries Ltd.

Key Findings Of The Study

  • North America garnered 36.33% share of the global MS therapies market in 2018.

  • By type, immunosuppressants segment is anticipated to grow with the highest CAGR throughout the forecast period.

  • The injectable segment accounted for 33.10% share of the market in 2018.

North America accounted for the largest share in the global MS therapies market in 2018, owing to increase in demand for MS therapeutic products. In addition, the factors that boost the growth of the MS therapies market in North America include easy availability of MS therapies and increase favorable reimbursement policies by government for MS treatment. Moreover, the presence of key players such as Pfizer, Novartis, and Bayer in the region contributes to the growth of market. Furthermore, it has been observed that rates of MS are higher in regions further from equator; thus, the prevalence of MS is alarmingly high in North America. For instance, according to the Government of Canada, in 2014-15, approximately 77,000 people were suffering from MS. In addition, according to the Global Burden of Disease Study, 2016, North America accounted for highest age-standardized MS prevalence at 164.6 per 100,000 population. Therefore, rise in prevalence has led to surge in demand for MS therapies in the region, thereby fueling the growth of the market.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
 
 

First time buyer?
Check offers and discount on this report
To get this report

Click Here
 
 

quote Multiple Sclerosis Therapies Market by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019–2026 quote

View Report
 
 

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

WHY ALLIED MARKET RESEARCH?

INFLALLIBLE METHODOLOGY

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

ANALYST SUPPORT

For complete satisfaction

CUSTOMIZATION

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
rep-img

Published Date Mar 2024

Hairbrush Market

Download Sample
rep-img

Published Date Mar 2024

Debt Security Market

Download Sample
rep-img

Published Date Mar 2024

Wood Adhesives Market

Download Sample

Buy Full Version
"Multiple Sclerosis Therapies Market"
Purchase Enquiry

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers